Contact
searchSearch
HMP Global
Login

From The Field

From the Field
Cost and Clinical Implications of Utilizing Homologous Recombination Deficiency Status to Guide First-Line Maintenance Therapy Selection in Advanced Ovarian Cancer
12/02/2024
Daniel Simmons, PharmD, MS; Rebecca Stone, MD; James Ryan, MSc; Jigna Bhalla, PharmD; Kimmie McLaurin, MS
This study models the clinical outcomes and costs associated with utilizing an HRD biomarker-guided (BMG) approach to first-line AOC maintenance compared with a non-biomarker-guided (NBMG) approach.
This study models the clinical outcomes and costs associated with utilizing an HRD biomarker-guided (BMG) approach to first-line AOC maintenance compared with a non-biomarker-guided (NBMG) approach.
This study models the clinical...
12/02/2024
Journal of Clinical Pathways
From the Field
Bridging the Gap Between Oncologists and Payers: Impact of an EHR-Embedded CDS Tool in Oncology Clinical Pathway (OCP) Adherence
08/15/2024
Anna Bolha, MPAS, PA; Rebecca Maniago, PharmD, BCOP; Nina Sardesh; Taylor Dias-Foundas; James Roose, MA; Colin Harvey; Marcello Ricottone; Eric Weber; Susan Sabo-Wagner, MSN, RN, OCN, NEA-BC; Brian Patrick Mulherin, MD; Andrew Hertler, MD, FACP; James Hamrick, MD, MPH
In this report, researchers discuss a real-world study of treatment selection patterns across American Oncology Network medical oncologists, which analyzed pathway adherence rates before and after a pilot project where Evolent level 1...
In this report, researchers discuss a real-world study of treatment selection patterns across American Oncology Network medical oncologists, which analyzed pathway adherence rates before and after a pilot project where Evolent level 1...
In this report, researchers...
08/15/2024
Journal of Clinical Pathways
From the Field
Shifting the Paradigm: The Impact of AI at the Point of Care in Cancer Treatment
06/03/2024
Taylor Dias-Foundas
This report explores the transformative impact of artificial intelligence (AI) in health care, emphasizing its potential paradigm shift and current deployment in oncology.
This report explores the transformative impact of artificial intelligence (AI) in health care, emphasizing its potential paradigm shift and current deployment in oncology.
This report explores the...
06/03/2024
Journal of Clinical Pathways
From the Field
Bringing Value to Health Care
06/03/2024
Lili Brillstein, MPH
This paper provides insights and perspective from each constituent involved in shaping health care payment and delivery throughout the US.
This paper provides insights and perspective from each constituent involved in shaping health care payment and delivery throughout the US.
This paper provides insights and...
06/03/2024
Journal of Clinical Pathways
From the Field
Comprehensive Genomic Testing: Tissue Stewardship and Best Practices
02/12/2024
Mary Nesline, MS; Heidi Ko, DO; Jeffrey M. Conroy, BS; Maureen E. Cooper, BS; Shakti H. Ramkissoon, MD, PhD; Faezeh Koohestani, PhD; Durga Prasad Dash, PhD; Brian Caveney, MD, JD, MPH; Shengle Zhang, MD; Eric Severson, MD, PhD; Michelle F. Green, PhD; Zachary Wallen, PhD; Sarabjot Pabla, PhD; Marcia Eisenberg, PhD; Kyle C. Strickland, MD; Stephanie Hastings, PhD; Rebecca A. Previs, MD, MS
Rebecca A. Previs, MD, et al provide an overview of current genomic testing methodologies and offer guidelines on best practices for tissue stewardship and preanalytic practices for successful comprehensive genomic profiling.
Rebecca A. Previs, MD, et al provide an overview of current genomic testing methodologies and offer guidelines on best practices for tissue stewardship and preanalytic practices for successful comprehensive genomic profiling.
Rebecca A. Previs, MD, et al...
02/12/2024
Journal of Clinical Pathways
From the Field
Real-world Utilization of Second-line Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy Versus Active Surveillance in Community Oncology Practice Patients With Advanced Ovarian Cancer
05/19/2022
Junxin Shi, PhD; Yiqiong Xie, PhD, MPH; Katrine L. Wallace, PhD; Robert Reid, MD
Dr Wallace and colleagues analyzed second-line poly(ADP-ribose) polymerase inhibitor (PARPi) maintenance therapy in a real-world setting to understand how it is being utilized and the resultant impact on patients’ disease course.
Dr Wallace and colleagues analyzed second-line poly(ADP-ribose) polymerase inhibitor (PARPi) maintenance therapy in a real-world setting to understand how it is being utilized and the resultant impact on patients’ disease course.
Dr Wallace and colleagues...
05/19/2022
Journal of Clinical Pathways
From the Field
Real-World Characteristics and Outcomes of Patients With Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Treated With First-Line Bendamustine + Rituximab
04/20/2022
Erica DiMaria, MD; David Susman; Derek Nay, MD; Rouslan Kotchetkov, MD, PhD; Lauren Gerard, MD
Dr Kotchetkov and colleagues assessed the pattern of B-R administration, efficacy and safety in adult patients with indolent non-Hodgkin lymphoma and mantle cell lymphoma with advanced disease and co-morbidities in the real-world setting.
Dr Kotchetkov and colleagues assessed the pattern of B-R administration, efficacy and safety in adult patients with indolent non-Hodgkin lymphoma and mantle cell lymphoma with advanced disease and co-morbidities in the real-world setting.
Dr Kotchetkov and colleagues...
04/20/2022
Journal of Clinical Pathways
From the Field
Incidence and Cost of Radical Prostatectomy and Radiotherapy for NCCN Low-risk Prostate Cancer in Utah
03/16/2022
Bryan Crawford; Jesse Gygi; Brandon Barney, MD; Libby Petersen; McKenzie Bell; Zoya Sandhu; David Gill, MD; Jonathan Tward, MD; Jessica Baumgartner
David Gill, MD , and colleagues analyzed rates of treatment for men with low-risk disease who were treated at either The Huntsman Cancer Institute or Intermountain Healthcare facilities, and modeled the costs associated with the presumptive...
David Gill, MD , and colleagues analyzed rates of treatment for men with low-risk disease who were treated at either The Huntsman Cancer Institute or Intermountain Healthcare facilities, and modeled the costs associated with the presumptive...
David Gill, MD , and colleagues...
03/16/2022
Journal of Clinical Pathways
From the Field
Streamlining Institutional Pathway Processes: The Development and Implementation of a Pathology Molecular Consult to Facilitate Convenient and Efficient Ordering, Fulfillment, and Reporting for Tissue Molecular Tests
02/15/2022
Sharad Mathur, MD; Janet Barrett; Michael Goodman, MD; Maryam Abdo, MBChB; Susie Willis; Linda Verkruyse, MD; Joseph Modzelewski; Robert Hoyt, MD; Hanan Elsarraj, MD; Daniel Mettman, MD
Daniel Mettman, MD, and colleagues detail the work of two mid-sized VA medical centers in collectively developing and implementing a consult process as part of their oncology clinical pathways to standardize ordering, fulfillment, and...
Daniel Mettman, MD, and colleagues detail the work of two mid-sized VA medical centers in collectively developing and implementing a consult process as part of their oncology clinical pathways to standardize ordering, fulfillment, and...
Daniel Mettman, MD, and...
02/15/2022
Journal of Clinical Pathways
From the Field
Referral Patterns and Treatment Preferences in Patients With Advanced Prostate Cancer: Differences Between Medical Oncologists and Urologists
10/20/2021
Skyler Hime Rupard, MS; Ajeet Gajra, MD, FACP; Yolaine J. Jeune-Smith, PhD; Bruce A. Feinberg, DO
Ajeet Gajra, MD, FACP, et al assessed the differences between medical oncologists and urologists regarding perceptions on timing of referral and treatment sequence decisions for patients with advanced prostate cancer
Ajeet Gajra, MD, FACP, et al assessed the differences between medical oncologists and urologists regarding perceptions on timing of referral and treatment sequence decisions for patients with advanced prostate cancer
Ajeet Gajra, MD, FACP, et al...
10/20/2021
Journal of Clinical Pathways
JCP January/February 2025

Current Issue

February 2025
Volume 11
Issue 1
Current Issue
Issue Archive

Special Reports

Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use